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New analytical methods developed at the facilities here, based on two ultra-sensitive mass spectrometry (MS) techniques, in-
ductively coupled plasma sector field mass spectrometer with a desolvator system (Aridus-ICP-SFMS) and accelerator MS
(AMS), have been applied in this work for the reassessment of 239Pu in alpha spectrometry (AS) planchets corresponding to
spiked human urine samples. The obtained 239Pu minimum detectable activities (MDAs) values by Aridus-ICP-SFMS and
AMS were 3 fg (∼6.92 mBq) and 0.4 fg (∼0.92 mBq), respectively, per sample, which are much better than those attainable
by AS [50 fg (∼115.3 mBq) of 239Pu per sample, approximately]. Therefore, it is demonstrated that the MS techniques
employed in this work are very powerful tools for internal dosimetry studies in human urine samples, giving excellent results
when the reassessment of AS planchets is needed (samples with a Pu concentration below or at the MDA levels measurable
by AS). This work is the continuation of an article published in J. Anal. At. Spectrom. 25 (1410–1415) 2010.
INTRODUCTION
The successful measurement and assessment of in-
ternal exposure to radioactivity in dosimetry studies
are highly dependent on the instrumental capabilities
for measuring radionuclides in biological samples
(urine, feces, blood or other secretions)(1, 2).
Normally, during the Pu bioassay of human urine
samples, it is mandatory to preconcentrate and
purify the Pu fraction. In the case of mass spectrom-
etry (MS) techniques, it is usually important to
prevent the presence of 238U in the sample, because
it can interfere with the signal of the major Pu
isotope 39Pu (T1/2¼24 110 y), and also to avoid
matrix effects. For these purposes, ion-exchange or
solid-phase extraction chromatography is extensively
used in worldwide laboratories(3 – 8).
Alpha spectrometry (AS) is the most commonly
used radioanalytical technique for the determination
of Pu in routine bioassay studies, due to its simpli-
city and low cost. However, this method is very
time-consuming and it cannot resolve the 239Pu and
240Pu peaks because of their very similar energies
(5.15 and 5.16 MeV). Analytical results from AS are
therefore expressed as the sum of the 239Pu and 240Pu
activity concentration (i.e. 239þ240Pu). Additionally,
this technique shows some sensitivity shortcomings
when the involved 239þ240Pu activity levels are below
0.3 mBq per sample (1.3 pg of 239Pu per sample),
due to the noise associated with the detector and
the poor statistics(9). On the other hand, several
parameters, such as counting efficiency, chemical
yield, sample counting time, tracer activity used and
background condition the precision and accuracy of
the results for low-level samples and, therefore,
the minimum detectable activity (MDA) of AS(10–12).
Because of its excellent detection sensitivity, MS
techniques are useful tools for measuring 239Pu at
sub-fg levels, and also 240Pu/239Pu atomic ratios,
which would be impossible to measure using conven-
tional radioactive decay counting techniques. Due to
the requirements imposed by the International
Commission on Radiological Protection (ICRP),
techniques capable of measuring 239/240/241Pu iso-
topes at concentrations of 1 fg l21 in urine
samples are becoming mandatory(13, 14).
Different MS techniques, such as inductively coupled
plasma (ICP) MS(3–6), Thermal ionisation MS
(TIMS)(15, 16) and accelerator MS (AMS)(14, 17, 18), are
good candidates for the dosimetric control of the popu-
lation exposed to ionising radiation, opening up the
possibility of identifying and quantifying small
amounts of different radionuclides in a sample, and
also offering isotopic composition unattainable by
radioactive counting techniques(19–22).
ICP-MS is one of the most suitable methods for
the analysis of actinides at ultratrace levels, in par-
ticular 239Pu, due to its high sensitivity, good
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accuracy and precision and generally simple sample
preparation procedure versus AS(3). However, the ac-
curate determination of Pu isotopes by ICP-MS is
hampered by both spectral and non-spectral interfer-
ences. For the analysis of Pu, the most common
interferences are 238UHþ and 238UH2
þ, which inter-
fere with the 239Pu and 240Pu isotopes, respectively,
due to the presence of U. To avoid these problems,
two complementary solutions are usually applied:
the preconcentration and purification of the Pu frac-
tion using ion-chromatography resins(4, 5), and/or
the reduction of uranium hydride formation using
special sample introduction systems, such as micro-
nebulizers with desolvator system(6).
On the other hand, AMS has recently been
demonstrated to be a competitive technique for the
precise and accurate determination of Pu at sub-fg
levels in urine bioassay samples. It features a high
sensitivity with virtually no matrix effects (high re-
jection of molecular isobaric interferences), allowing
the identification of abnormal activities of Pu with
no special chemical requirements(7).
The aim of this study was to develop and validate
an analytical method for the reassessment of 239Pu
in AS planchets containing small amounts of 239Pu
(from 8 to 40 fg per sample), using the Aridus deso-
lvator coupled with an ICP-SFMS, and a 1-MV
compact AMS system. This is specially interesting
for the authors’ research centre, CIEMAT (Research
Center of Environment and Energy and Technology),
where there is a big stock of Pu electrodeposits from
human urine samples from the population of
Palomares (Almeria, Spain), affected by a nuclear ac-
cident in 1966, and from professionally exposed
people.
MATERIALS AND REAGENTS
Instrumentation
Spectrophotometry and AS
Creatinine determination was carried out by using a
spectrophotometer Zuzi, Model 4211/20 (Auxilab
S.L., Spain). AS measurements were performed with
an Alpha Analyst Integrated Alpha Spectrometer
(Canberra, TECNASA S.L., Spain) equipped with
Passivated Implanted Planar Silicon detectors. These
detectors have an active area of 450 mm2 and their
nominal alpha-peak energy resolution, expressed as
full-width at half-maximum, is 18 keV. The plan-
chets (Pu sources) were placed at 1.5 mm from the
detector surface. For the evaluation of the data, the
Genie 2000 v.2.2 software (Canberra) was used.
HR-ICP-MS instrumentation
Pu quantification was carried out with an Element
XR Mass Spectrometer (Thermo Fisher Scientific,
Bremen, Germany). The sample introduction system
employed was an Aridus desolvator (CETAC
Technologies, Inc., USA) with a Microflow nebulizer
PFA-100 (Elemental Scientific Inc., USA). Aqueous
samples were introduced to the desolvator in the
continuous flow mode by using an auto sampler
CETAC ASX-520 (CETAC Technologies, Inc.,
USA). The ICP torch was shielded with a grounded
platinum electrode (GuardElectrodeTM, Thermo
Scientific, Germany).
Accelerator MS
The measurements of 239Pu were performed using
the 1-MV compact AMS system set up at the
Centro Nacional de Aceleradores (CNA, Seville,
Spain). The system was designed and manufactured
by High Voltage Engineering Europa (HVEE,
Amersfoort, Holland).
Materials and reagents
239Pu and 242Pu standards were obtained from
National Physical Laboratory (NPL, UK).
Standards were diluted with 2 M HNO3 to obtain
stock solutions with a concentration of 20.3 mBq
ml21 (140.4 ng l21) of 242Pu and 7.9 mBq ml21 (3.4
ng l21) of 239Pu. 237Np (chosen as external standard
for ICP-SFMS measurements) was obtained from
Amersham International plc (UK). This standard
was diluted with 0.1 M HCl to obtain a stock solu-
tion with a concentration of 3.256 mBq ml21 (123
ng l21). For ICP-SFMS mass calibration, a certified
multi-element solution XXIII (Ba, B, Co, Fe, Ga,
In, K, Li, Lu, Na, Rh, Sc, Y, Tl and U) from Merck
(Germany) was used. The rest of the salts and solu-
tions were prepared using analytical grade reagents
from Merck. High-purity water (.18 MV cm21)
was obtained from a Milli-Q Element A10 Century
(Millipore Ibe´rica, Spain). Nitric acid was purified
by sub-boiling distillation (Duopur, Milestone S.r.l.,
Italy). Certified Ar gas (99.999 %) was supplied by
Air Liquide (Spain). Certipurw iron ICP standard
(Merck, Germany) and 500-mesh pure aluminium
powder (Alfa-Aesar, UK) were employed for prepar-
ation of the AMS cathodes. AG1X2 anion-exchange
chromatography resins (Bio-Rad Laboratories S.A.,
Spain) were used for Pu purification. The ICP-
SFMS measurements were carried out in a clean
room (ISO 6 class) at 24+18C.
Experimental
The different features of the method for the extrac-
tion and purification of 239Pu in human urine
samples and the reassessment of AS planchets for
ICP-SFMS and AMS determinations are shown in
the diagram in Figure 1.
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Figure 1. Schematic diagram for the preparation procedure of urine samples and measurements of Pu by AS, Aridus-ICP-
SFMS and AMS: (1) collection of sample (time: 24 h); (2) co-precipitation (24 h); (3) Mineralisation (2 h); (4)
radiochemistry (3 h); (5) electrodeposition (2 h); (6) recovery of Pu from planchets (24 h) and (7) preparation of the
cathodes for AMS (3 h) and reassessment of 239Pu by Aridus-ICP-SFMS and AMS. This figure appears in colour in the
online version of Radiation Protection Dosimetry.
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Creatinine measurements
Measurements of creatinine concentrations in urine
have been commonly used in the laboratory to esti-
mate 24 h excretion of radionuclides from urine
samples collected in a day, then 14 samples of 24 h
human urine (Vsample¼1725+114 ml) were collected
from several healthy adult male volunteers. The ana-
lytical procedure was initiated the same day of the
collection by the determination of creatinine content
in the urine samples, in order to check whether
those met the requirements needed previous to bio-
assay. The method is based on the Jaffe´ reaction:
addition of sodium picrate into the urine and for-
mation of a red-coluored complex (sodium
picramate)(23). The colour intensity is directly pro-
portional to the concentration of creatinine at a spe-
cific wavelength (520 nm), which is measured with a
spectrophotometer(24).
Co-precipitation
The method carried out for co-precipitation is
described in Kuwabara and Noguchi(8) and Robredo
et al.(9) The 24 h urine samples were transferred into
respective graduated cylinders, acidified with concen-
trated HNO3 to pH¼1, and heated in a hot plate
with magnetic stirring at 808C during 2 h. Then, the
hot samples were spiked with known amounts of
242Pu (8.4 pg) as internal standard, and 239Pu (from
8 to 40 fg, see Table 1). Next, 1 ml of concentrated
orthophosphoric acid was added, continuing the
heating and the stirring for a further 1 h. Then, the
Pu was co-precipitated by the addition of concen-
trated ammonium hydroxide until pH¼9, keeping
the same conditions for 1 h. The precipitate was
allowed to settle overnight and then separated by
decanting and centrifugation. The supernatant was
discarded, and the graduated cylinder was washed
several times with 0.5 M HNO3. The washings were
also transferred into the centrifuge tube, and the pre-
cipitate was dissolved with 5 ml21 of 8 M HNO3
plus slow addition 3 ml of concentrated H2O2. The
procedural blanks (unspiked urine samples) were
processed in the same way.
Mineralisation, radiochemistry, electrodeposition
and preparation of the cathodes for AMS
A summary of the processes involved in this section
is given in Figure 1. A detailed description has been
provided in previous studies(25).
Recovery of Pu for planchets reassessment
In order to determine the radiochemical yield during
Pu purification, the samples were previously mea-
sured by AS. After that, the extraction of the
electrodeposits was carried out by dipping the plan-
chets into 20 ml of 5 % HNO3 overnight. Next, the
planchets were rinsed with 5 % HNO3 and the
resulting solutions were heated to dryness, diluted to
10 ml of the same acid in volumetric flasks, and
divided in two twin aliquots for the Aridus-ICP-
SFMS and the AMS determinations. In the case of
the ICP-SFMS aliquots, 4.4 fg of 237Np were also
added as an external standard.
RESULTS AND DISCUSSION
Creatinine test
The Pu is a long-lived radionuclide that is excreted
from the human body in very small amounts, which
cannot always be easily detected by AS. The recom-
mendations for good routine analysis of Pu in urine
establish that the sample must contain the creatinine
equivalent of, at least, of 24 h excretion(26). This
contributes to minimise the uncertainty of the results
normalised to 24 h excretion, specially when analys-
ing spot urine samples(7, 13, 27). Therefore, the deter-
mination of creatinine in urine is essential for
monitoring the excretion of long-lived radionuclides
and it is also a decisive test for accepting or rejecting
the sample(28). In this work, the average creatinine
concentration was 1.1+0.13 g l21 (n¼15), which is
in agreement with the ICRP-89 recommendations
for accepting urine samples for dosimetry studies(10).
Treatment of sample and purification of Pu
The co-precipitation of Pu with calcium phosphate
in ammonia medium was performed to pre-concen-
trate it, because it is adequate to perform in human
urine at a sub-pg/l concentration level of Pu.
Normally, the routine bioassay of long-lived radio-
nuclides requires mineralisation of the sample, which
is usually carried out by wet ashing of the precipitate
followed by muffle furnace incineration(9). This
process is very time-consuming and tedious.
Therefore, in this work, the mineralisation was per-
formed by microwave-assisted acidic digestion (8 M
HNO3 and concentrated H2O2) of the calcium phos-
phate precipitate, which accelerates the preparation
of the sample.
When using MS and radiochemistry techniques
for Pu quantification in low-level samples, the elim-
ination of matrix elements contained in the sample
is a must. In this work, this was achieved using
anion-exchange resins (BioRad AG1X2). The purifi-
cation of Pu using AG1X2 resin does not present
significant drawbacks in contrast to other Pu purifi-
cation processes which, in principle, are faster(5). In
case, the necessary time for processing 10 samples
was 2–4 h. Moreover, as measured by AS, AG1X2
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resin offers an excellent chemical recovery of the Pu
fraction in urine samples (Table 1).
Optimisation of Aridus-ICP-SFMS parameters
The instrumental settings were optimised for the
quantification of 237Np 239Pu and 242Pu.
Optimisation was performed in three steps:
(1) Tuning the parameters of Aridus (argon and ni-
trogen flow) to obtain the maximum intensities
for 115In and 238U isotopes, using a dilution
(1:10) of the certified multielement solution in
low resolution mode. The signal intensity for
these isotopes was about 7.0105 cps and
1.0106 cps, respectively, and the 238U oxides
content in the plasma was 0.6 %.
(2) Optimisation of maximum ion intensity for
242Pu and minimum background at m/z¼239
using a 242Pu standard solution of 0.4 pg l21.
The background signal obtained during this step
was 0.3+0.1 cps to m/z¼239. Additionally, a
stability test was also performed for monitoring
the signal of 237Np, 238U, 239Pu, 240Pu and 242Pu
isotopes (10, 0.1, 32, 2.7 and 42 pg l21, respect-
ively) in standard samples of these isotopes
during 15 min.
(3) Optimisation of the method for the measure-
ment of 237Np, 238U, 239Pu, 240Pu and 242Pu iso-
topes. Instrumental operation conditions are
summarised in Table 2.
Reassessment of the Pu by MS techniques
The main problem when measuring 239Pu by ICP-
SFMS appears when U is present in the sample (mo-
lecular isobaric interference due to the formation of
238U1Hþ in the plasma), and also from the tailing
effect of the 238U peak, which leads to an increase in
the background signal at m/z¼239. Some alterna-
tives have been considered in the literature in order
to avoid these problems: one option consists in using
a low-flow micronebulizer coupled with a membrane
desolvator as sample introduction system (Aridus)(6),
and the second option consists in using deuterated
water as sample solvent(29). In this work, the influ-
ence of 238U on the background signal at m/z¼239
was investigated using the Aridus-ICP-SFMS. Thus,
a certified standard solution of 0.1 ppb of 238U in
HNO3 5 % [(
238U) 105(239Pu)samples] was mea-
sured, obtaining a background signal at m/z¼239 of
1.0+0.3 cps (n¼10). The background signal
obtained with HNO3 5 % blanks at m/z¼239 was
0.3+0.1 cps, indicating that the contribution of
238U to the 239Pu signal is negligible in these condi-
tions. These results are in good agreement with
other works for the analysis of Pu in urine
samples(3).
External calibration was employed during the
reassessment of 239Pu and 242Pu in AS planchets for
Aridus-ICP-SFMS analysis (Figure 2). All the solu-
tions (blanks, standards and samples) were spiked
with 237Np as an external standard, to monitor the
instrument stability during the measurements
(Figure 3).
The results indicate the excellent chemical recov-
ery achieved with the proposed extraction process
for the reassessment of Pu from AS planchets
Table 2. Instrumental conditions optimised for the
measurement of Pu from planchets by Aridus-ICP-SFMS.
Solution uptake rate 0.1 ml min21
RF power 1300 W
Cool gas flow rate 16.0 l min21
Auxiliary gas flow rate 0.70 l min21
Nebulizer gas flow rate 1.194 l min21
Ion extraction lens
potential
22000 V
Mass resolution (m/Dm) 300
Isotope 237Np; 238U; 239Pu;
240Pu; 242Pu
Samples per peak 100
Settling time 10 ms
Sample time 10 ms
Points per width 10
Peak shift 1.0
Mass window 100 %
Integration window 20 %
Scan type E-Scan
Detection mode Triple (ion counting,
analogue and Faraday)
Total analysis time per
sample
3 min
Sampler/skimmer cone Nickel
Aridus desolvator Sweep gas (Ar): 4.57 ml min21
Nitrogen flow: 6 ml min21
Nebulizer Microflow nebulizer PFA-100
Table 1. Results of radiochemical yield for Pu (measured by
AS). All the samples were initially spiked with 8.4 pg of
242Pu.
Sample 239Pu added
(fg)a
242Pu measured
(pg)
Recovery yield of
242Pu (%)
1 8 6.49+0.43 78
2 10 6.82+0.58 82
3 10 6.24+0.50 75
4 17 6.74+0.43 81
5 20 6.49+0.70 78
6 26 6.74+0.67 81
7 32 6.24+0.67 75
8 35 8.07+0.80 97
9 40 6.07+0.66 73
a239þ240Pu measured is below the MDA.
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(Table 3). However, it must be pointed out that, in
the case of AMS measurements, the presence of
milligrams of iron coming from the planchet (due to
corrosion) can affect the sensitivity of the analysis
due to a dilution effect on the sample(7).
The calculation of the 239Pu content in the initial
urine samples was performed by the isotope dilution
method, considering the 239Pu/242Pu isotopic ratio
measured by Aridus-ICP-SF-MS in the Pu fraction
leached from the planchets (90 %) and the amount
of spike initially added to the samples; these results
are shown in Table 3, column two and the results
were confirmed by AMS. The levels of 239Pu concen-
tration by both methods no showed significant dif-
ference in results.
Limit of detection (LOD) and MDA for 239Pu
using Aridus-ICP-SFMS were calculated from the
analysis of a series of 10 procedural blanks, and
compared with those reported in previous publica-
tions by AS, AMS and conventional ICP-SFMS
(Table 4)(25).
The obtained results with the new set up are
about one order of magnitude lower than those
reported by conventional ICP-SFMS, and compares
with those obtained by AMS. LOD for Pu by AS
was calculated using the Currie criterion(30) and,
then, MDA was calculated considering the LOD, the
average chemical yield for Pu (80+7 %) and the
total volume of urine (1725+114 ml). In the case of
Aridus-ICP-SFMS and AMS, the LOD and AMD
calculations were made as described in a previous
work(7, 25).
Accordingly with(8), and assuming an acute intake
by inhalation of a type S substance, an excretion of
2.3 10– 6 (Bq of Pu/Bq intake) is predicted at the
first day of the intake(13). Therefore, considering the
MDA levels for Pu reported here (7.41026 Bq per
sample for Aridus-ICP-SFMS, and 1.01026 Bq
per sample for AMS), it can be concluded that the
method developed in this paper provides enough
sensitivity to perform the reassessment of planchets
when AS is unable to give any information during
internal dosimetric controls. Minimum detectable
doses can be then calculated at given days after
Figure 2. Calibration curves for 239Pu and 242Pu measured
by Aridus-ICP-SFMS.
Figure 3. Instrumental stability of the Aridus-ICP-SFMS,
monitored during the analyses using 237Np as external
standard.
Table 3. Reassessment of 239Pu on planchets by Aridus-
ICP-SFMS and AMS.
Sample Aridus-ICP-SFMS AMS
239Pu (fg)a 239Pu (fg)b 239Pu (fg)b
1 5.4+0.9 8.1+1.7 8.2+0.8
2 6.5+0.8 10.1+1.7 9.8+0.6
3 7.2+0.5 10.0+1.2 10.3+0.8
4 13.7+0.7 17.1+1.7 17.4+0.9
5 13.9+0.8 20.0+2.1 19.5+0.9
6 19.3+1.2 27.1+3.0 25.8+1.4
7 22.4+1.2 32.3+3.4 31.6+1.6
8 30.6+1.4 36.1+3.4 34.8+1.3
9 27.6+1.4 40.1+4.0 38.3+1.8
aResult obtained of 239Pu with external calibration by
Aridus-ICP-SFMS.
bCalculated mass of 239Pu used method of isotope dilution
method, considering the 239Pu/242Pu isotopic ratio
measured.
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intake from the MDA of the method, urinary excre-
tion rate (24 h urine samples) and dose coefficient. If
the urine is collected on the first day of acute intake
of type S 239Pu after an accident, the minimum de-
tectable dose of the method is 0.03 mSv for Aridus-
ICP-SFMS, and 0.004 mSv for AMS. One year after
the intake, the minimum detectable dose of this
method is lower than 0.5 mSv for both techniques.
CONCLUSIONS
Different analytical methods for quantifying 239Pu
in urine with MS techniques have been optimised
and evaluated in this paper. The results indicate that
they are suitable for dosimetric monitoring of the
staff occupationally exposed to Pu. The analytical
techniques employed (Aridus-ICP-SFMS and AMS)
have shown success in these kinds of controls, exhi-
biting excellent sensitivity for Pu analysis, and a re-
markable increase of productivity when compared
with AS. This opens the possibility of giving support
to the internal dosimetry service for routine analysis
in those cases where the Pu content is below the
MDA achieved by AS, both in urine samples and in
the reassessment of planchets.
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